Production (Stage)
Immunic, Inc.
IMUX
$0.8516
$0.06328.02%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 5.29M | 4.01M | 4.36M | 4.49M | 5.15M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 26.83M | 25.63M | 25.73M | 22.81M | 23.88M |
Operating Income | -26.83M | -25.63M | -25.73M | -22.81M | -23.88M |
Income Before Tax | -25.47M | -25.18M | -24.37M | -21.38M | -29.58M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -25.47M | -25.18M | -24.37M | -21.38M | -29.58M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -25.47M | -25.18M | -24.37M | -21.38M | -29.58M |
EBIT | -26.83M | -25.63M | -25.73M | -22.81M | -23.88M |
EBITDA | -26.78M | -25.60M | -25.68M | -22.78M | -23.86M |
EPS Basic | -0.25 | -0.25 | -0.24 | -0.21 | -0.30 |
Normalized Basic EPS | -0.15 | -0.16 | -0.15 | -0.13 | -0.16 |
EPS Diluted | -0.25 | -0.25 | -0.24 | -0.21 | -0.30 |
Normalized Diluted EPS | -0.15 | -0.16 | -0.15 | -0.13 | -0.16 |
Average Basic Shares Outstanding | 101.34M | 100.70M | 101.27M | 101.27M | 97.30M |
Average Diluted Shares Outstanding | 101.34M | 100.70M | 101.27M | 101.27M | 97.30M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |